Bartsch R - Search Results

1

Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.

Mair MJ, Bartsch R, Le Rhun E, Berghoff AS, Brastianos PK, Cortes J, Gan HK, Lin NU, Lassman AB, Wen PY, Weller M, van den Bent M, Preusser M. Mair MJ, et al. Among authors: bartsch r. Nat Rev Clin Oncol. 2023 Jun;20(6):372-389. doi: 10.1038/s41571-023-00756-z. Epub 2023 Apr 21. Nat Rev Clin Oncol. 2023. PMID: 37085569 Review.

2

Brain metastases: pathobiology and emerging targeted therapies.

Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A. Preusser M, et al. Among authors: bartsch r. Acta Neuropathol. 2012 Feb;123(2):205-22. doi: 10.1007/s00401-011-0933-9. Epub 2012 Jan 3. Acta Neuropathol. 2012. PMID: 22212630 Review.

3

Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.

Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F, Gnant M, Zielinski CC, Steger GG. Bartsch R, et al. Eur J Cancer. 2012 Sep;48(13):1932-8. doi: 10.1016/j.ejca.2012.03.002. Epub 2012 Mar 27. Eur J Cancer. 2012. PMID: 22459763 Clinical Trial.

4

Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.

Preusser M, Fülöp G, Berghoff AS, Heinzl H, Steger GG, Greil R, Zielinski CC, Bartsch R. Preusser M, et al. Among authors: bartsch r. Oncologist. 2012;17(7):e13-7. doi: 10.1634/theoncologist.2012-0115. Epub 2012 Jun 27. Oncologist. 2012. PMID: 22744818 Free PMC article.

5

Primary systemic treatment of breast-cancer brain metastases.

Bartsch R, Preusser M. Bartsch R, et al. Lancet Oncol. 2013 Jan;14(1):8-9. doi: 10.1016/S1470-2045(12)70449-7. Epub 2012 Nov 2. Lancet Oncol. 2013. PMID: 23122783 No abstract available.

6

Optimal management of brain metastases from breast cancer. Issues and considerations.

Bartsch R, Berghoff AS, Preusser M. Bartsch R, et al. CNS Drugs. 2013 Feb;27(2):121-34. doi: 10.1007/s40263-012-0024-z. CNS Drugs. 2013. PMID: 23239265 Review.

7

Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.

Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, Gnant M, Steger GG, Zielinski CC, Bartsch R. Berghoff AS, et al. Among authors: bartsch r. Breast J. 2013 Mar-Apr;19(2):149-55. doi: 10.1111/tbj.12070. Epub 2013 Jan 27. Breast J. 2013. PMID: 23350584 Clinical Trial.

8

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.

Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M. Zagouri F, et al. Among authors: bartsch r. Breast Cancer Res Treat. 2013 May;139(1):13-22. doi: 10.1007/s10549-013-2525-y. Epub 2013 Apr 16. Breast Cancer Res Treat. 2013. PMID: 23588955 Review.

9

Breast cancer brain metastases responding to primary systemic therapy with T-DM1.

Bartsch R, Berghoff AS, Preusser M. Bartsch R, et al. J Neurooncol. 2014 Jan;116(1):205-6. doi: 10.1007/s11060-013-1257-5. Epub 2013 Sep 25. J Neurooncol. 2014. PMID: 24065570 No abstract available.

10

Invasion patterns in brain metastases of solid cancers.

Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, Goodman SL, Weller M, Schittenhelm J, Preusser M. Berghoff AS, et al. Among authors: bartsch r. Neuro Oncol. 2013 Dec;15(12):1664-72. doi: 10.1093/neuonc/not112. Epub 2013 Sep 30. Neuro Oncol. 2013. PMID: 24084410 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

492 results

Search Page